High-grade serous ovarian cancer

What changed: High-grade serous ovarian cancer

Cancer page →

Every dated change on the records linked to High-grade serous ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result4Milestone7This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordHigh-grade serous ovarian cancer
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022MilestoneMirvetuximab soravtansine
Mirvetuximab soravtansine approved for platinum-resistant disease
A milestone in how this cancer is treated.

2020 · 1

2020Trial resultDESKTOP III / ENGOT-ov20
DESKTOP III / ENGOT-ov20 reported
OS 53.

2019 · 3

2018 · 2

2014 · 1

2014MilestoneOlaparib
Olaparib: first PARP inhibitor approved
A milestone in how this cancer is treated.

2011 · 1

2011MilestoneBevacizumab
Bevacizumab improves progression-free survival (GOG-0218, ICON7)
A milestone in how this cancer is treated.

2007 · 1

2007MilestoneHigh-grade serous ovarian cancer
Fallopian tube fimbria identified as the origin of serous cancer
A milestone in how this cancer is treated.

1996 · 1

1996MilestoneCarboplatin
Carboplatin-paclitaxel becomes standard (GOG 111 and successors)
A milestone in how this cancer is treated.